Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development

Clin Pharmacol Ther. 2018 Sep;104(3):484-494. doi: 10.1002/cpt.1034. Epub 2018 Feb 27.

Abstract

Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the "omics" approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.

Publication types

  • Historical Article
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Consumer Product Safety
  • Drug Development / history
  • Drug Development / methods*
  • Drug Discovery / history
  • Drug Discovery / methods*
  • Genetic Predisposition to Disease
  • Genomics
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Precision Medicine
  • Respiratory Distress Syndrome / diagnosis
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / genetics
  • Respiratory Distress Syndrome / physiopathology
  • Respiratory System Agents / adverse effects
  • Respiratory System Agents / history
  • Respiratory System Agents / therapeutic use*
  • Risk Assessment
  • Translational Research, Biomedical / history
  • Translational Research, Biomedical / methods*

Substances

  • Respiratory System Agents